Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Lucia Y Chen, Santiago Thibaud, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath

Blood (2023) 142 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2023-190368

Published: 2023

Journal Articles

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Adolfo Aleman, Morgan Van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Lucia Y Chen, Bhaskar Upadhyaya, Jessica Nardulli, Kseniya Serebryakova, Katerina Kappes, Hayley Jackson, Charles Gleason, Oliver Van Oekelen, Carlos Cordon-Cardo, Ania Wajnberg, Florian Krammer, Miriam Merad, Sundar Jagannath, Viviana Simon, Samir Parekh

Blood (2023) 142 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2023-187260

Published: 2023

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Blood (2023) 142 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2023-181936

Published: 2023

Journal Articles

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Joshua Richter, Cesar Rodriguez, Larysa J Sanchez, Santiago Thibaud, Hearn Jay Cho, Shambavi Richard

Blood (2023) 142 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2023-177749

Published: 2023

Journal Articles

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Santiago Thibaud, Jerrel Catlett, Saoirse Bodnar, MD Babu Mia, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Sundar Jagannath, Shambavi Richard, Samir Parekh

Blood (2023) 142 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2023-190772

Published: 2023

Journal Articles

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Candace Westgate, Gilles Salles, Stephannie Shih, Margarita Lopatin, Kathryn N. Kurtzman, Katerina Kappes, Oliver Venn, Samir Parekh, Jeffrey M. Venstrom, Anas Younes, Rita Shaknovich

Blood (2023) 142 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2023-186481

Published: 2023

Journal Articles

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Darren Denjay Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Hearn Jay Cho, Joshua Richter, Larysa J Sanchez, Santiago Thibaud, Cesar Rodriguez, Shambavi Richard

Blood (2023) 142 (Supplement 1): 92.

https://doi.org/10.1182/blood-2023-188310

Published: 2023

Journal Articles

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Santiago Thibaud, William Genthe, Saoirse Bodnar, Alessandro Lagana, Jane Houldsworth, Ajai Chari, Adriana C Rossi, Cesar Rodriguez, Larysa J Sanchez, Shambavi Richard, Joshua Richter, Kenan Onel, Sundar Jagannath, Tehilla Brander, Samir Parekh

Blood (2023) 142 (Supplement 1): 534.

https://doi.org/10.1182/blood-2023-190878

Published: 2023

Journal Articles

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Blood (2023) 142 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2023-184409

Published: 2023

Journal Articles

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

Selma Bekri, Simone Katz, Geoffrey Kelly, Travis Dawson, Darwin D'Souza, Michael Mason, Alexandre Alloy, Shameek Biswas, Seunghee Kim-Schulze, Sacha Gnjatic, Samir Parekh, Sundar Jagannath, Alessandro Lagana, Hearn Jay Cho

Blood (2023) 142 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2023-189882

Published: 2023

Journal Articles

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

Blood (2023) 142 (10): 887–902.

https://doi.org/10.1182/blood.2022019419

Published: 2023

Includes: Supplemental data

Journal Articles

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Blood (2023) 141 (7): 756–765.

https://doi.org/10.1182/blood.2022017848

Published: 2023

Includes: Supplemental data

Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Blood (2022) 140 (Supplement 1): 3480–3482.

https://doi.org/10.1182/blood-2022-169102

Published: 2022

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Alessandro Lagana, Santiago Thibaud, David T. Melnekoff, Paula Restrepo, Violetta Leshchenko, Jonathan McCafferty, Scott Newman, Abbi Kern, David Corrigan, Feras Hantash, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Shambavi Richard, Ajai Chari, Hearn J. Cho, Sundar Jagannath, Joshua Richter, Samir Parekh

Blood (2022) 140 (Supplement 1): 4388–4390.

https://doi.org/10.1182/blood-2022-166572

Published: 2022

Journal Articles

Extramedullary Relapse Post CAR-T

Shambavi Richard, Guido Lancman, Adriana Rossi, Ajai Chari, Samir Parekh, Larysa Sanchez, Cesar Rodriguez, Hearn J. Cho, Joshua Richter, Santiago Thibaud, Kiah Purcell, Elizabeth Aronson, Daniel Verina, Juliet Escalon, Karen Louw, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 4301–4302.

https://doi.org/10.1182/blood-2022-170119

Published: 2022

NARROW

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Extramedullary Relapse Post CAR-T

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only